CD4 and neoplasm: A recent study by Benvenuto et al. found that the number of B lymphocytes, CD4+ and CD8+ T cells, macrophages, and natural killer cells increased within the tumor microenvironment upon bortezomib treatment in a head and neck cancer mouse model [156].